Analysts: Optimer Pharmaceuticals Inc (OPTR.OQ)
OPTR.OQ on NASDAQ Stock Exchange Global Select Market
12.48USD
1 Aug 2013
12.48USD
1 Aug 2013
Price Change (% chg)
$-0.03 (-0.24%)
$-0.03 (-0.24%)
Prev Close
$12.51
$12.51
Open
$12.64
$12.64
Day's High
$12.65
$12.65
Day's Low
$12.48
$12.48
Volume
558,582
558,582
Avg. Vol
327,918
327,918
52-wk High
$16.77
$16.77
52-wk Low
$8.66
$8.66
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Hold | -0.54 | December | 2 Aug 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 2 | 4 | 4 | 5 |
| (2) OUTPERFORM | 0 | 1 | 1 | 2 |
| (3) HOLD | 7 | 5 | 5 | 3 |
| (4) UNDERPERFORM | 1 | 2 | 2 | 2 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.70 | 2.42 | 2.42 | 2.17 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 9 | 23.24 | 26.74 | 19.01 | 36.28 |
| Quarter Ending Dec-13 | 9 | 25.60 | 30.29 | 18.91 | 39.41 |
| Year Ending Dec-13 | 10 | 88.83 | 99.64 | 77.89 | 149.10 |
| Year Ending Dec-14 | 9 | 137.03 | 170.30 | 92.12 | 198.66 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | 9 | -0.54 | -0.46 | -0.63 | -0.32 |
| Quarter Ending Dec-13 | 9 | -0.51 | -0.42 | -0.63 | -0.29 |
| Year Ending Dec-13 | 10 | -2.32 | -2.15 | -2.79 | -1.21 |
| Year Ending Dec-14 | 9 | -1.05 | 0.18 | -1.74 | -0.04 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 21.09 | 19.43 | 1.65 | 7.83 |
| Quarter Ending Dec-12 | 18.05 | 19.52 | 1.46 | 8.11 |
| Quarter Ending Sep-12 | 16.03 | 17.88 | 1.85 | 11.52 |
| Quarter Ending Jun-12 | 43.84 | 49.76 | 5.92 | 13.49 |
| Quarter Ending Mar-12 | 28.77 | 14.38 | 14.39 | 50.01 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | -0.41 | -0.65 | 0.23 | -56.63 |
| Quarter Ending Dec-12 | -0.38 | -0.64 | 0.26 | -67.10 |
| Quarter Ending Sep-12 | -0.64 | -0.56 | 0.08 | -12.36 |
| Quarter Ending Jun-12 | -0.07 | -0.01 | 0.06 | -85.14 |
| Quarter Ending Mar-12 | -0.38 | -0.71 | 0.33 | -86.30 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-13 | 23.24 | 23.36 | 23.49 | 23.70 | 36.28 |
| Quarter Ending Dec-13 | 25.60 | 25.81 | 26.03 | 26.34 | 39.41 |
| Year Ending Dec-13 | 88.83 | 89.16 | 90.30 | 90.89 | 149.10 |
| Year Ending Dec-14 | 137.03 | 138.21 | 140.06 | 139.81 | 198.66 |
| Earnings (per share) | |||||
| Quarter Ending Sep-13 | -0.54 | -0.52 | -0.51 | -0.51 | -0.32 |
| Quarter Ending Dec-13 | -0.51 | -0.50 | -0.49 | -0.48 | -0.29 |
| Quarter Ending Dec-13 | -2.32 | -2.29 | -2.24 | -2.23 | -1.21 |
| Quarter Ending Dec-14 | -1.05 | -1.02 | -0.99 | -0.99 | -0.04 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-13 | 0 | 1 | 0 | 1 |
| Quarter Ending Dec-13 | 0 | 1 | 0 | 1 |
| Year Ending Dec-13 | 1 | 1 | 1 | 2 |
| Year Ending Dec-14 | 0 | 1 | 0 | 2 |
| Earnings | ||||
| Quarter Ending Sep-13 | 0 | 1 | 0 | 1 |
| Quarter Ending Dec-13 | 0 | 1 | 0 | 1 |
| Year Ending Dec-13 | 0 | 1 | 1 | 2 |
| Year Ending Dec-14 | 0 | 1 | 1 | 2 |
- Cubist to pay up to $1.6 billion for two antibiotics makers
- UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers
- Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion
- CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln
- Cubist bid for Optimer before sale process began: sources
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Earnings vs.
Estimates